cas 1442437-21-9|| where to buy 4-hydroxy-6-oxo-1H-pyridazine-3-carboxylic acid

Nombre del producto:4-hydroxy-6-oxo-1H-pyridazine-3-carboxylic acid

IUPAC Name:4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxylic acid

Unidad de embalaje	Stock disponible	Precio($)
CM325395-5g	in stock	źȀǕ
CM325395-10g	in stock	ƞňŔ
CM325395-25g	in stock	ǕșǕ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1442437-21-9 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :1442437-21-9; Fórmula molecular:C5H4N2O4; Punto de fusión:-; Código de sonrisas:O=C(C(C(O)=C1)=NNC1=O)O; Densidad:

: Número de catálogo:CM325395; Peso molecular:156.1; Punto de ebullición:; Nº Mdl:MFCD30489098; Almacenamiento:

: Pyridazines; Pyridazine, also known as o-diazobenzene, is a six-membered heterocyclic compound containing two nitrogen heteroatoms in the 1 and 2 positions with a special structure and a wide biological activity. Pyridazine is more and more popular in drug development, and a variety of pyridazine drugs have been developed and marketed. From the perspective of the therapeutic field, pyridazine drug molecules are mainly used for tumor treatment, but also involve in many therapeutic fields such as inflammation, hypertension and cardiovascular disease. With the increase and in-depth of research, pyridazine drugs will play more roles in the treatment of diseases.

: Deucravacitinib; BMY announced new four-year Sotyktu (deucravacitinib) data demonstrating durable response rates and consistent safety in moderate-to-severe plaque psoriasis. Deucravacitinib is a specific, oral, intracellular TYK2 inhibitor that targets immune responses driven by type 1 IFN and IL-23 that contribute to psoriasis pathogenesis, including IL-17 production and Th1/Th17 polarization.